Veru to raise $100M through stock offering to fund cancer pharmaceutical research


    A Miami-based company focused on developing new biopharmaceuticals for the treatment of breast and prostate cancers plans to raise $100 million through a common stock offering.

    Veru (Nadsaq: VERU) priced 6.4 million shares of its common stock at $15.50 a share, according to a Feb. 17 filing with the U.S. Securities and Exchange Commission. The offering is expected to close Feb. 22.